These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 12353631

  • 1. Inhibitory properties of antitumor prostaglandins against topoisomerases.
    Suzuki K, Uyeda M.
    Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of topoisomerases by antitumor prostaglandins.
    Suzuki K, Shono F, Uyeda M.
    Biosci Biotechnol Biochem; 1998 Oct; 62(10):2073-5. PubMed ID: 9836448
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II.
    Suzuki K, Yahara S, Hashimoto F, Uyeda M.
    Biol Pharm Bull; 2001 Sep; 24(9):1088-90. PubMed ID: 11558576
    [Abstract] [Full Text] [Related]

  • 4. 2070-DTI, a topoisomerase inhibitor produced by Streptomyces sp. strain No. 2070.
    Suzuki K, Doi S, Yahara S, Uyeda M.
    J Enzyme Inhib Med Chem; 2003 Dec; 18(6):497-503. PubMed ID: 15008514
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
    Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, Yamada Y.
    Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interaction of strong DNA-intercalating bioreductive compounds with topoisomerases I and II.
    Rosenzweig HS, Papadopoulou MV, Bloomer WD.
    Oncol Res; 2005 Oct; 15(4):219-31. PubMed ID: 17822282
    [Abstract] [Full Text] [Related]

  • 15. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, Kasprzyk PG, Prévost G, Bigg DC.
    Cancer Res; 2004 Jul 15; 64(14):4942-9. PubMed ID: 15256467
    [Abstract] [Full Text] [Related]

  • 16. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
    Peleg R, Romzova M, Kogan-Zviagin I, Apte RN, Priel E.
    BMC Cancer; 2014 Dec 03; 14():910. PubMed ID: 25472619
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT.
    Cancer Res; 1996 Jun 01; 56(11):2573-83. PubMed ID: 8653700
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.